中华普通外科杂志
中華普通外科雜誌
중화보통외과잡지
CHINESE JOURNAL OF GENERAL SURGERY
2009年
5期
394-397
,共4页
杜义安%程向东%郭剑民%黄灵%周立新%张则伟
杜義安%程嚮東%郭劍民%黃靈%週立新%張則偉
두의안%정향동%곽검민%황령%주립신%장칙위
癌,肝细胞%射频%免疫,细胞
癌,肝細胞%射頻%免疫,細胞
암,간세포%사빈%면역,세포
Carcinoma,hepatocellular%Radiofrequency%Immunity,cellular
目的 探讨开腹射频综合治疗对多发性大肝癌患者生存期的影响及机理.方法 回顾性分析2003年1月至2007年1月在我院治疗的多发性大肝癌45例患者的治疗方法.单纯肝动脉栓塞化疗(TACE组)20例,手术多发灶局部切除+TACE治疗(局部切除组)13例,开腹射频消融治疗+TACE(开腹射频组)12例.分析各组患者治疗前后T淋巴细胞亚群水平的变化,并比较各组的完全缓解率及生存率.结果 治疗后4周射频组患者CD4+、NK细胞水平、CD4+/CD8+比值比治疗前明显升高(P<0.05),而手术局部切除组及TACE组无明显变化,局部切除组术后短期内还出现了免疫抑制现象.开腹射频组、局部切除组与TACE组的完全缓解率分别为41.70%,46.20%,25.50%,3组比较差异无统计学意义(x2=1.81,P>0.05).3组的1.5年与2年的生存率分别为75.00%、69.20%、30%(x2=7.96,P<0.05),以及50.00%、23.10%、10.00%(x2=18.98,P<0.05).3组的平均生存期分别为26.56个月、21.04个月、16.41个月(x2=14.69,P<0.001).开腹射频组的总生存率明显高于其他组(x2=4.635,P<0.05).开腹射频组与局部切除组比较,开腹射频组患者带瘤生存时间延长(x2=4.615,P<0.05).结论 以开腹射频为主的综合治疗通过提高肝癌患者的细胞免疫功能明显延长患者生存时间.
目的 探討開腹射頻綜閤治療對多髮性大肝癌患者生存期的影響及機理.方法 迴顧性分析2003年1月至2007年1月在我院治療的多髮性大肝癌45例患者的治療方法.單純肝動脈栓塞化療(TACE組)20例,手術多髮竈跼部切除+TACE治療(跼部切除組)13例,開腹射頻消融治療+TACE(開腹射頻組)12例.分析各組患者治療前後T淋巴細胞亞群水平的變化,併比較各組的完全緩解率及生存率.結果 治療後4週射頻組患者CD4+、NK細胞水平、CD4+/CD8+比值比治療前明顯升高(P<0.05),而手術跼部切除組及TACE組無明顯變化,跼部切除組術後短期內還齣現瞭免疫抑製現象.開腹射頻組、跼部切除組與TACE組的完全緩解率分彆為41.70%,46.20%,25.50%,3組比較差異無統計學意義(x2=1.81,P>0.05).3組的1.5年與2年的生存率分彆為75.00%、69.20%、30%(x2=7.96,P<0.05),以及50.00%、23.10%、10.00%(x2=18.98,P<0.05).3組的平均生存期分彆為26.56箇月、21.04箇月、16.41箇月(x2=14.69,P<0.001).開腹射頻組的總生存率明顯高于其他組(x2=4.635,P<0.05).開腹射頻組與跼部切除組比較,開腹射頻組患者帶瘤生存時間延長(x2=4.615,P<0.05).結論 以開腹射頻為主的綜閤治療通過提高肝癌患者的細胞免疫功能明顯延長患者生存時間.
목적 탐토개복사빈종합치료대다발성대간암환자생존기적영향급궤리.방법 회고성분석2003년1월지2007년1월재아원치료적다발성대간암45례환자적치료방법.단순간동맥전새화료(TACE조)20례,수술다발조국부절제+TACE치료(국부절제조)13례,개복사빈소융치료+TACE(개복사빈조)12례.분석각조환자치료전후T림파세포아군수평적변화,병비교각조적완전완해솔급생존솔.결과 치료후4주사빈조환자CD4+、NK세포수평、CD4+/CD8+비치비치료전명현승고(P<0.05),이수술국부절제조급TACE조무명현변화,국부절제조술후단기내환출현료면역억제현상.개복사빈조、국부절제조여TACE조적완전완해솔분별위41.70%,46.20%,25.50%,3조비교차이무통계학의의(x2=1.81,P>0.05).3조적1.5년여2년적생존솔분별위75.00%、69.20%、30%(x2=7.96,P<0.05),이급50.00%、23.10%、10.00%(x2=18.98,P<0.05).3조적평균생존기분별위26.56개월、21.04개월、16.41개월(x2=14.69,P<0.001).개복사빈조적총생존솔명현고우기타조(x2=4.635,P<0.05).개복사빈조여국부절제조비교,개복사빈조환자대류생존시간연장(x2=4.615,P<0.05).결론 이개복사빈위주적종합치료통과제고간암환자적세포면역공능명현연장환자생존시간.
Objective To study the effects of intraoporative radio-frequency ablation on immune functions and survival of patients with multiple large hepatic cancer. Methods Forty five admitted patients with multiple large hepatic cancer from January 2003 to January 2007 were devided into: simple hepatic artery embohzation chemotherapy group (TACE group, n = 20) , local resection of multiple lesion + TACE (LR group, n = 13), and TACE + intraoperative radio-frequency ablation (IRFA group, n = 12). The changes of peripheral blood T-cell subsets were evaluated using flow cytometry, and a comparison of the complete remission rate and survival rate between the 3 groups was made and the survival rate analyzed with Kaplan-Meier method, the validity check with long-rank method. Results CD4+ , NK, and CD4+/ CD8+radio significantly increased 4 weeks after treatment only in IRFA group. The immune function was suppressed during the first week after treatment in local resection group. Tumor complete remission rate in IRFA group, local resection group and simple TACE group were 41.70%, 46. 20% and 25.50% respectively, the difference was not statistically significant between the 3 groups (x2 = 1.81, P > 0.05). the 1.5 year and 2.0 year survival rate in the 3 groups were 75.00%, 69. 20%, 30% (x2 = 7.96, P < 0.05) and 50.00%, 23.10%, 10. 00% respectively (x2 = 18.98 ,P <0.05), the mean survival period of patients in the 3 groups was 26. 56 months, 21.04 months, and 16.41 months respectively (x2 = 14.69, P < 0.001). Kaplan-Meier survival curve showed the overall survival rate in the IRFA group was significantly higher than that of the other 2 groups (x2 = 4.635, P < 0.05). The prolongation of the survival period in patient with multiple macronodular hepatic cancer after IRFA treatment was mainly due to the prolongation of survival period in tumor bearing patients (IRFA group vs LR group, x2= 4.615, P < 0.05). Conclusion IRFA prolongs the survival of patients with multiple macranodular hepatic cancer possibly by enhancing the functions of cellular immunity.